| Inverness Medical Innovations Declares Dividend on Its Series B Convertible Perpetual Preferred Stock (PR Newswire) Inverness Medical Innovations, Inc. , a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, has declared a dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock . Â The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of $3.00 divided by 97% of the average of the volume-weighted average price per share of the Series B stock on the New York Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Â Inverness will pay cash in lieu of any fractional shares resulting from the dividend. Â The dividend is payable on July 15, 2010 to holders of record of Series B stock at the close of business on July 1, 2010. Â us.rd.yahoo.com |
Genzyme Catches Eye of Others Sanofi-Aventis may not be the only big drug maker interested in Genzyme, after news of Sanofi's interest in the U.S. biotech company became public. online.wsj.com |
Merck, SciClone Tapped in Fed Pharma Probe The Burrill Report submits: By Michael FitzhughMerck (MRK) and SciClone (SCLN) have become the latest targets of ongoing federal investigations intended to curtail direct and indirect payments to foreign officials by companies with a substantial U.S. presence. The investigations, launched by U.S. Justice Department and the Securities and Exchange Commission, are examining potential violations of the Foreign Corrupt Practices Act, a law prohibiting foreign bribery in business and instituting accounting record-keeping requirements intended to detect and prevent such illegal payments. Complete Story » seekingalpha.com |
FDA Chief Looks to Antibiotic Resistance The FDA is intensifying its focus on problems caused by antibiotic resistance among humans and feed animals through the widespread use of those drugs over the past several decades. online.wsj.com |
FDA Warns Mead Johnson on Enfamil Packaging The FDA warned Mead Johnson about the packaging for some of the company's Enfamil infant formulas. online.wsj.com |